Possible involvement of C5/C5a in the efferent and elicitation phases of contact sensitivity

Journal of Immunology

Volumn 156, Issue 12, 1996, Pages 4644-4650

  Tsuji, Ryohei F ^a,b   Kikuchi, Mamoru ^a   Askenase, Philip W ^b  

^a KIKKOMAN CORPORATION   (Japan)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C5A; L 156602; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BLOOD VESSEL PERMEABILITY; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTACT SENSITIVITY; EFFECTOR CELL; ENDOTHELIUM CELL; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE CONTRACTION;

EID: 0029949312     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Askenase, P. W. Effector and regulatory mechanisms in delayed-type hypersensitivity (DTH). In Allergy: Principles and Practice, 4th Ed. E. Middleton, Jr., C. E. Reed, E. F. Ellis, and N. F. Atkinson, eds. C. V. Mosby Co., St. Louis, pp. 362-389.
2. Fong, T. A. T., and T. R. Mosmann. 1989. The role of IFN-γ in delayed-type hypersensitivity mediated by Th1 clones. J. Immunol. 143:2887.
3. Piguet, P. F., G. E. Grau, C. Hauser, and P. Vassalli. 1991. Tumor necrosis factor is a critical mediator in hapten-induced irritant and contact hypersensitivity reactions. J. Exp. Med. 173:673.
4. Schwarz, A., C. Kronke, F. Trautinger, Y. Aragane. P. Neuner, T. A. Luger, and T. Schwarz. 1993. Pentoxifylline suppresses irritant and contact hypersensitivity reactions. J. Invest. Dermatol. 101:549.
5. + T lymphocytes. Immunol. Today 9:268.
6. Van Loveren, H., R. Meade, and P. W. Askenase. 1983. An early component of delayed-type hypersensitivity mediated by T cells and mast cells. J. Exp. Med. 157:1604.
7. Van Loveren, H., and P. W. Askenase. 1984. Delayed-type hypersensitivity is mediated by a sequence of two different T cell activities. J. Immunol. 133:2397.
8. +T cell populations that mediate delayed-type hypersensitivity. J. Immunol. 133:2402.
9. -, and expresses IL-3 receptors, but no IL-2 receptors. J. Immunol. 143:3125.
10. Herzog, W.-R., I. Millet, N. R. Ferreri, R. Ramabhadran, J. Schreurs, and P. W. Askenase. 1990. An antigen-specific DTH-initiating cell clone: functional, phenotypical, and partial molecular characterization. J. Immunol. 144:3667.
11. Ptak, W., W.-R. Herzog, and P. W. Askenase. 1991. Delayed-type hypersensitivity initiation by early-acting cells that are antigen mismatched or MHC incompatible with late-acting, delayed-type hypersensitivity effector T cells. J. Immunol. 146:469.
12. Ptak, W., P. W. Askenase, R. W. Rosenstein, and R. K. Gershon. 1982. Transfer of an antigen-specific immediate hypersensitivity-like reaction with an antigen-binding factor produced by T cells. Proc. Natl. Acad. Sci. USA 79:1969.
13. Van Loveren, H., R. E. Ratzlaff, K. Kato, R. Meade, T. A. Ferguson, G. M. Iverson, C. A. Janeway, and P. W. Askenase. 1986. Immune serum from mice contact-sensitized with picryl chloride contains an antigen-specific T cell factor that transfers immediate cutaneous reactivity. Eur. J. Immunol. 16:1203.
14. Meade, R., H. Van Loveren, H. Parmentier, G. M. Iverson, and P. W. Askenase. 1988. The antigen-binding T cell factor PCl-F sensitizes mast cells for in vitro release of serotonin: comparison with monoclonal IgE antibody. J. Immunol. 141:2704.
15. Matsuda, H., H. Ushio, V. Paliwal, W. Ptak, and P. W. Askenase. 1995. Adoptive cell transfer of contact sensitivity initiation mediated by nonimmune cells sensitized with monoclonal IgE antibodies. J. Immunol. 154:5080.
16. Ameisen, J.-C., R. Meade, and P. W. Askenase. 1989. A new interpretation of the involvement of serotonin in delayed-type hypersensitivity: serotonin-2 receptor antagonists inhibit contact sensitivity by an effect on T cells. J. Immunol. 142: 3171.
17. Tsuji, R. F., J. Magae, K. Nagai, and M. Yamasaki. 1992. A novel in vivo screening method for immunomodulating substances: development of an assay system. Biosci. Biotech. Biochem. 56:1497.
18. Tsuji, R. F., M. Uramoto, H. Koshino, N. M. Tsuji, J. Magae, K. Nagai, and M. Yamasaki. 1992. Preferential suppression of delayed-type hypersensitivity by L-156,602, a C5a receptor antagonist. Biosci. Biotech. Biochem. 56:1686.
19. Tsuji, R. F., J. Magae, K. Nagai, and M. Yamasaki. 1992. Effects of L-156,602, a C5a receptor antagonist, on mouse experimental models of inflammation. Biosci. Biotech. Biochem. 56:2034.
20. Hensens, O. D., R. P. Borris, L. R. Koupal, C. G. Caldwell, S. A. Currie, A. A. Haidri, C. F. Homnick, S. S. Honeycutt, S. M. Lindenmayer, C. D. Schwartz, B. A. Weissberger, H. B. Woodruff, D. L. Zink, L. Zitano, J. M. Fieldhouse, T. Rollins, M. S. Springer, and J. P. Springer. 1991. L-156,602, a C5a antagonist with a novel cyclic hexadepsipeptide structure from Streptomyces sp. MA6348. J. Antibiol. 44:249.
21. Frank, M. M., and L. F. Fries. 1991. The role of complement in inflammation and phagocytosis. Immunol. Today 12:322.
22. Shin, H. S., R. Snyderman, E. Friedman, A. Mellors, and M. M. Mayer. 1968. Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science 162:361.
23. Fernandez, H. N., P. M. Henson, A. Otani, and T. E. Hugli. 1978. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J. Immunol. 120:109.
24. Cochrane, C. G., and H. J. Mueller-Eberhard. 1968. The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J. Exp. Med. 127:371.
25. Rocha e Silva, M., and M. Aronson. 1952. Histamine release from the perfused lung of the guinea pig by serotoxin (anaphylatoxin). Br. J. Exp. Pathol. 33:577.
26. Rocha e Silva, M., O. Bier, and M. Aronson. 1951. Histamine release by anaphylatoxin. Nature 168:465.
27. Dias da Silva, W., and I. H. Lepow. 1967. Complement as a mediator of inflammation. II. Biological properties of anaphylatoxin prepared with purified components of human complement. J. Exp. Med. 125:921.
28. Meuer, S., U. Ecker, U. Hadding, and D. Bitter-Suermann. 1981. Platelet-serotonin release by C3a and C5a: two independent pathways of activation. J. Immunal. 126:1506.
29. Slimier, N. P., W. E. Brocklehurst, C. M. Bloor, and T. E. Hugh. 1981. Anaphylatoxin-mediated contraction of guinea pig lung strips: a nonhistamine tissue response. J Immunol. 126:2258.
30. Churchill, W. H., Jr., R. M. Weintraub, T. Borsos, and H. J. Rapp. 1967. Mouse complement: the effect of sex hormones and castration on two of the late-acting components. J. Exp. Med. 125:657.
31. Ptak, W., G. P. Geba, and P. W. Askenase. 1991. Initiation of delayed-type hypersensitivity by low doses of monoclonal IgE antibody: mediation by serotonin and inhibition by histamine. J Immunol. 146:3929.
32. Gershon, R. K., P. W. Askenase, and M. D. Gershon. 1975. Requirement for vasoactive amines for production of delayed-type hypersensitivity skin reactions. J. Exp. Med. 142:732.
33. Lavaud, P., F. Rodrigue, C. Carre, C. Touvay, J.-M. Mencia-Huerta, and P. Braquet. 1991. Pharmacologic modulation of picryl chloride-induced contact dermatitis in the mouse. J. Invest. Dermatol. 97:101.
34. Tsuji, R. F., J. Yamakoshi, M. Uramoto, H. Koshino, M. Saito, M. Kikuchi, and T. Masuda. 1995. Anti-inflammatory effects and specificity of L-156,602: comparison of effects on Concanavalin A and zymosan-induced footpad edema, and contact sensitivity response. Immunopharmacology 29:79.
35. Nicholson-Weller, A., and J. A. Halperin. 1993. Membrane signaling by complement C5b-9, the membrane attack complex. Immunol. Res. 12:244.
36. Sims, P. J., and T. Wiedmer. 1991. The response of human platelets to activated components of the complement system. Immunol. Today 12:338.
37. Policy M. J., and R. L. Nachman. 1979. Human complement in thrombin-mediated platelet function: uptake of the C5b-9 complex. J. Exp. Med. 150:633.
38. Polley M. J., R. L. Nachman, and B. B. Weksler. 1981. Human complement in arachidonic acid transformation pathway in platelets. J. Exp. Med. 153:257.
39. Schwartz, H. J., and G. B. Naff. 1971. The effect of complement depletion by cobra venom factor on delayed hypersensitivily reactions. Proc. Soc. Exp. Biol. Med. 138:1041.
40. Yamamoto, S., C. J. Dunn, F. Capasso, D. A. Deporter, and D. A. Willoughby. 1975. Quantitative studies on cell-mediated immunity in the pleural cavity of guinea-pigs. J. Pathol. 117:65.
41. Willoughby, D. A., L. Polak, and J. L. Turk. 1968. Suppression of contact hypersensitivity and acute inflammation by anti-complement serum. Nature 219: 192.
42. Neveu, T., and G. Biozzi. 1965. The effect of decomplementation on delayed-type hypersensitive reactions to a conjugated antigen in rats. Immunology 9:303.
43. Ravetch, J. V. 1994. Fc receptors: rubor redux. Cell 78:553.
44. Lawrence, D. A., and R. F. Shell. 1978. Susceptibility of C5-deficient mice to listeriosis: modulation by concanavalin A. Cell. Immunol. 39:336.
45. Jungi, T. W., and D. D. McGregor. 1979. Role of complement in the expression of delayed-type hypersensitivity in rats: studies with cobra venom factor. Infect. Immun. 23:633.